Hypertrophic cardiomyopathy (HCM) is diagnosed primarily through echocardiography, with a confirmed diagnosis when the left ventricular wall measures 15 mm or thicker in at least one segment. That threshold drops to 13 mm if you have a known genetic mutation or a first-degree relative with the condition. Getting to that point typically involves a combination of physical exam findings, an electrocardiogram, imaging, and sometimes genetic testing.
What a Physical Exam Can Reveal
Not everyone with HCM has a detectable murmur, but when the condition causes obstruction in the heart’s outflow tract, it produces a distinctive sound. The murmur is medium-pitched with a crescendo-decrescendo pattern, heard best along the left side of the breastbone. It radiates toward the base of the neck but not into the carotid arteries, which helps distinguish it from a similar-sounding aortic valve problem.
What makes this murmur particularly useful diagnostically is how it responds to simple maneuvers. When you bear down (the Valsalva maneuver) or stand up quickly, both of which reduce the volume of blood in the heart, the murmur gets louder. When you squat, lie down, or raise your legs, the murmur quiets. This behavior is nearly unique to HCM and can raise suspicion even before any imaging is done.
Electrocardiogram Findings
An ECG is abnormal in the vast majority of people with HCM, which makes it a useful initial screening tool. The patterns are varied, though. Some are highly suggestive of HCM: pathological Q-waves (detected in up to 53% of patients, often early in the disease), deep S-waves in the right-sided chest leads, and high voltage in the left-sided leads indicating thickened heart muscle. Q-waves paired with an upright T-wave in the same lead are fairly specific to HCM and look different from the Q-waves caused by a heart attack.
Repolarization changes are common too, including ST depression and T-wave inversions. Giant, deeply inverted T-waves raise suspicion for a specific subtype called apical HCM, where the thickening is concentrated at the tip of the heart. In some patients, the only ECG clue is a single inverted T-wave in one of the lateral leads. Standard voltage criteria for left ventricular hypertrophy, on their own, appear in fewer than 2% of HCM patients, so voltage alone is not a reliable marker.
Echocardiography: The Core Diagnostic Test
Echocardiography (cardiac ultrasound) is the primary tool for diagnosing HCM. It directly measures wall thickness, identifies where the thickening is located, and evaluates how the heart fills and empties. The 15 mm wall thickness cutoff applies to adults without a family history; for those with an affected relative or a known gene mutation, 13 mm is enough to confirm the diagnosis.
Beyond wall thickness, echocardiography measures the pressure gradient in the left ventricular outflow tract. A gradient of 30 mmHg or higher at rest or with exertion, caused by the mitral valve leaflet being pulled into the outflow path during contraction, defines obstructive HCM. Symptoms from obstruction typically become limiting once that gradient reaches 50 mmHg or more. If you have symptoms but a resting gradient below 50 mmHg, exercise echocardiography or a Valsalva maneuver during the scan can unmask a gradient that only appears with exertion.
Cardiac MRI for Deeper Detail
Cardiac MRI provides higher-resolution images than echocardiography and is especially valuable when ultrasound images are suboptimal or when the diagnosis is uncertain. It can detect thickening in areas the echocardiogram sometimes misses, particularly at the apex of the heart.
The real advantage of MRI is its ability to detect scarring within the heart muscle using a technique called late gadolinium enhancement. A contrast dye highlights areas of fibrosis, and the extent of that scarring carries prognostic weight. When fibrosis involves more than 15% of the heart muscle, the risk of sudden cardiac death is substantially higher: one study found serious cardiac events in 34% of patients above that threshold, compared with 6% of those below it. This information helps guide decisions about whether a defibrillator is needed.
Ambulatory Heart Rhythm Monitoring
A Holter monitor, worn for 24 to 48 hours, is recommended at initial evaluation and then every one to two years. The primary goal is to detect non-sustained ventricular tachycardia, short bursts of rapid heart rhythm originating from the lower chambers. These episodes are a recognized risk factor for sudden cardiac death in HCM and often produce no symptoms at all, which is why routine monitoring matters even if you feel fine. If you have palpitations or lightheadedness, extended monitoring or an event recorder may be used until a correlation between symptoms and rhythm is established.
Genetic Testing
Genetic testing identifies mutations in the proteins that make up the heart’s contractile machinery. In familial cases, these sarcomere gene mutations account for roughly 60% of diagnoses. In broader clinical populations, the detection rate is lower, around 40 to 45%. A positive result confirms the genetic basis of the disease and, importantly, allows cascade testing of family members. A relative who carries the same mutation can be monitored before any thickening develops. A relative who tests negative can be reassured and spared years of surveillance.
A negative genetic test does not rule out HCM. Many patients have the disease without an identifiable mutation, and testing panels do not cover every possible gene involved.
Telling HCM Apart From Athlete’s Heart
This distinction matters because intense athletic training can thicken the heart wall enough to overlap with mild HCM, creating a gray zone that is common in competitive athletes. Several features help separate the two. In athlete’s heart, the left ventricular cavity is typically enlarged beyond 55 mm, a size that is rare in HCM, where the cavity is usually smaller than 45 mm. Diastolic filling, how the heart relaxes and fills between beats, is normal in athletes but almost always abnormal in HCM, detectable on Doppler ultrasound. If an athlete stops training for three to six months, the wall thickening from exercise typically regresses, while HCM-related thickening does not.
Screening for Family Members
Because HCM is inherited in an autosomal dominant pattern, meaning each child of an affected parent has a 50% chance of carrying the mutation, clinical screening of first-degree relatives is a standard part of the diagnostic process. The recommended schedule depends on age. Children under 12 generally do not need screening unless multiple family members are affected or there has been a premature death in the family. Between ages 12 and 20, screening with echocardiography and ECG is recommended every 12 to 18 months. From 21 to 60, the interval widens to every three to five years. After 60, routine screening is typically no longer recommended, since the disease usually manifests by that age if the gene is present.
If a specific mutation has been identified in the family through genetic testing, relatives can undergo a single blood test. Those who do not carry the mutation can stop imaging surveillance entirely.